MD Medical Group Reports 14% Deliveries Growth in 1H 2013
MD Medical Group Investments Plc (LSE: MDMG) (the “Group”), Russia’s leading provider of private women’s and children’s healthcare, announces operating results for the half year ended 30 June 2013[1].
Elena Mladova, Chief Executive Officer of MD Medical Group, said:
“We are pleased to post strong operating results for the period, with double-digit growth across all of our key performance indicators. Three factors in particular contributed to this growth.
“We have continued to expand our geographic footprint across Russia, for example with the successful acquisition of IDK Samara.
“We have expanded the range of our inpatient and outpatient services, with the opening of surgery, trauma and rehabilitation departments as well as a new diagnostics centre at Lapino hospital.
“And we continue to demonstrate leadership in developing new and innovative technologies within women’s health and pediatrics. We were pleased, for example, to have become the first company to offer Laparoscopic removal of abdominal cerclage.”
During the reporting period, the total number of deliveries increased by 14% from 1,570 to 1,792, outpacing the birth rate growth in Moscow (+1.3%) and Moscow region (+1.1%). The main driver for this growth was the successful ramp up at Lapino, with 521 deliveries in the first half of 2013. The number of deliveries at Perinatal Medical Centre (PMC) amounted to 1,271, a 19% y-o-y decrease on the back of strong base effect from the previous year, and approximately in line with the total annual deliveries during the three previous years – 2009-2011.
The number of outpatient treatments in the first half of 2013 increased by 32% to 273,910, up from 207,949 in the same period last year.
Inpatient admissions in the first half of 2013 grew by 18% to 13,992, up from 11,882 year-on-year.
IVF cycles increased by 20% during the reporting period, reaching a total of 2,335.
1H 2013 Operating Highlights
|
|
1H 2013 |
1H 2012 |
y-o-y, % |
1H 2011 |
|
Obstetrics and Gynaecology |
||||
|
Deliveries |
1,792 |
1,570 |
14% |
1,320 |
|
Deliveries at PMC |
1,271 |
1,570 |
-19% |
1,320 |
|
Deliveries at Lapino |
521 |
- |
- |
- |
|
Inpatient treatments (except deliveries) |
8,644 |
7,225 |
20% |
5,938 |
|
Out-patient treatments |
149,012 |
116,288 |
28% |
74,863 |
|
IVF |
2,335 |
1,953 |
20% |
1,175 |
|
|
||||
|
Paediatrics |
||||
|
Inpatient treatments |
4,788 |
4,657 |
3% |
3,435 |
|
Out-patient treatments |
101,423 |
79,455 |
28% |
47,664 |
|
Other medical services out-patient |
23,475 |
12,206 |
92% |
- |
|
Other medical services inpatient |
560 |
- |
- |
- |
|
|
|
|
|
|
|
Total deliveries |
1,792 |
1,570 |
14% |
1,320 |
|
Total Inpatient treatments |
13,992 |
11,882 |
18% |
9,373 |
|
Total Out-patient treatments |
273,910 |
207,949 |
32% |
122,527 |
|
Total IVF |
2,335 |
1,953 |
20% |
1,175 |
For further information please contact:Investors Media
EM – Moscow |
|
Consilium Strategic Communications – London Emma Thompson / Matthew Neal
Tel: +44 20 7920 2354 |
[1] MD Medical Group’s operating results for the reporting period include the results of recently acquired companies – IDK Samara (consolidated as of 01-04-2013) and M&C Irkutsk (consolidated as of 01-05-2013).
Forward-Looking Statements:
This press release contains forward looking statements, which are based on the Company’s current expectations and assumptions and may involve known and unknown risks and uncertainties that could cause actual results, performance or events to differ materially from those expressed or implied in such statements. The forward looking statements contained in this press release are based on past trends or activities and should not be taken that such trends or activities will continue in the future. It is believed that the expectations reflected in these statements are reasonable, but they may be affected by a number of variables which could cause actual results or trends to differ materially, including, but not limited to: conditions in the market, market position of the Company, earnings, financial position, cash flows, return on capital and operating margins, anticipated investments and economic conditions; the Company’s ability to obtain capital/additional finance; a reduction in demand by customers; an increase in competition; an unexpected decline in revenue or profitability; legislative, fiscal and regulatory developments, including, but not limited to, changes in environmental and health and safety regulations; exchange rate fluctuations; retention of senior management; the maintenance of labour relations; fluctuations in the cost of input costs; and operating and financial restrictions as a result of financing arrangements.
No statement in this press release is intended to constitute a profit forecast, nor should any statements be interpreted to mean that earnings or earnings per share will necessarily be greater or lesser than those for the relevant preceding financial periods for the Company. Each forward looking statement relates only as of the date of the particular statement.